Nargiz Majidova, Murat Sari, Fatma Akdag Kahvecıglu, Erkan Ozcan, Mutıanur Ozkorkmaz Akdag, Akıf Dogan, Sedat Yıldırım, Sermın Dınc Sonusen, Emıl Yunusov, Alper Yasar, Abdussamet Celebi, Nadıye Sever, Erkam Kocaaslan, Pınar Erel, Yesım Agyol, Ali Kaan Guren, Rukiye Arikan, Selver Işık, Ozlem Balvan, Caglayan Geredeli, Kazım Uygun, Ilhan Hacıbekiroğlu, Osman Kostek, İbrahim Vedat Bayoğlu
INTRODUCTION: Nasopharyngeal carcinoma (NPC) accounts for 0.01% of all carcinomas, and 70% of patients have locally advanced disease with a poor prognosis. The mainstay therapy is chemoradiotherapy (CRT), and concurrent administration of platinum-based agents and irradiation provides high local control rates. However, induction (neoadjuvant) chemotherapy (ICT) prior to chemoradiotherapy is recommended for large tumors with a high tumor burden at category 1 level. For induction chemotherapy, platinum-based doublet or triplet combination regimens are recommended...
April 2, 2024: Oncology Research and Treatment